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Abstract
Background
There are limited reports outlining the financial cost of treating cardiac implantable electronic
device (CIED) infection outside the United States. This study aimed to determine the aver-
age treatment cost of CIED infection in a large UK tertiary referral centre and compared
costs of different treatment pathways that are recognised in the management of CIED infec-
tion (early versus delayed re-implantation).
Methods
We retrospectively analysed cost and length of stay (LOS) data for consecutive patients
undergoing infected CIED extraction with cardiac resynchronization therapy (CRT-D [with
defibrillator], CRT-P [with pacemaker]), implantable cardioverter-defibrillators (ICDs) and
permanent pacemakers (PPMs).
Results
Between January 2013 and March 2015, complete data was available for 84 patients (18
[21.4%] CRT-D, 24 [28.6%] ICDs and 42 [50.0%] PPMs). When all cases were considered
the cost of infection ranged from £5,139 (PPM) to £24,318 (CRT-D). Considering different
treatment strategies; 41 (48.8%) underwent CIED extraction and re-implantation during the
same admission (early re-implant strategy (ER). 43 (51.2%) underwent extraction, but were
PLOS ONE | https://doi.org/10.1371/journal.pone.0206611 January 2, 2019 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Ahmed FZ, Fullwood C, Zaman M,
Qamruddin A, Cunnington C, Mamas MA, et al.
(2019) Cardiac implantable electronic device
(CIED) infections are expensive and associated
with prolonged hospitalisation: UK Retrospective
Observational Study. PLoS ONE 14(1): e0206611.
https://doi.org/10.1371/journal.pone.0206611
Editor: Yoshihiro Fukumoto, Kurume University
School of Medicine, JAPAN
Received: April 4, 2018
Accepted: October 16, 2018
Published: January 2, 2019
Copyright: © 2019 Ahmed et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The minimal data set
is in the Supporting Information Files.
Funding: The authors received no specific funding
for this work.
Competing interests: FZA has previously received
a research grant (unrelated to this study) funded by
Medtronic. There are no patents, products in
development or marketed products to declare. This
does not alter our adherence to all the PLOS ONE
policies on sharing data and materials.
then discharged home to be re-admitted for day-case re-implantation (delayed re-implant
strategy (DR)). Median LOS was significantly shorter in DR compared to ER (5.0 vs. 18.0
days, p<0.001). The total cost of CIED infection episode was similar for both treatment strat-
egies (median £14,241.48 vs. £14,741.70 including wearable defibrillator (Lifevest) and out-
patient antibiotics costs, ER vs. DR; p = 0.491).
Conclusion
CIED infections are expensive and associated with significant health-economic burden.
When all device types were considered, a DR strategy is associated with reduced LOS with-
out an increased cost penalty.
Introduction
Rates of cardiac implantable electronic device (CIED) implantation have increased in the last
decade. [1–5] However, rates of CIED infections are also increasing,[6, 7] and are associated
with significant morbidity and mortality. [1, 8, 9] In 2011, the average cost of combined medi-
cal and surgical treatment for a single CIED infection in the USA ranged between $28,676 and
$53,349.[8, 10] However, a detailed breakdown of the costs and health economic impact of
treating CIED infection in the UK has not yet been reported. [10, 11] In addition to the cost of
the device, there are multiple sources of potential expense; prolonged courses of antibiotics
may be necessary, pacing-dependent patients may require temporary pacing, and patients with
explanted implantable cardioverter defibrillators (ICDs) may need to remain in hospital for
monitoring or be discharged with a wearable defibrillator (Lifevest), designed to detect and
treat potentially life-threatening arrhythmias pending ICD re-implantation.[10]
A 2014 study reported the average cost of CIED infection in the UK to be £30,958 with a
mean length of stay (LOS) of 29.9 days, although this study was small and measuring the cost
of infection and was not the primary objective.[12] Different strategies are emerging for the
management of these patients; some undergo a “single-stage” procedure where the infected
device is removed and a new device is re-implanted during the same procedure. This approach
potentially carries the potential risk of re-infection of the new device; accordingly, our centre
has adopted a “two-stage” procedure for all patients, whereby a period of antibiotic therapy is
completed following extraction, and a new device re-implanted at a later date. With such a
strategy, some patients undergo re-implantation during the index hospitalisation (early re-
implantation (ER), whilst others are discharged and subsequently return for day-case re-
implantation at a later date (delayed re-implantation (DR). A DR strategy is often considered
when patients have persistent signs of infection, including delayed healing of the index site of
infection; or when clinically stable patients prefer to be managed in an outpatient setting whilst
awaiting re-implantation. In the current study, we aimed to determine the average treatment
cost of CIED infection in a large UK tertiary referral centre and to compare the cost of an ER
vs. DR strategy.
Methods
Study design
Retrospective analysis of clinical case records of patients undergoing extraction for CIED
infection at a single UK tertiary cardiothoracic centre. The principle outcomes were cost and
Cost of CIED infection
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length of stay. The study protocol, a data only study to examine data collected as part of routine
clinical care, was reviewed and approved by the institutional review board (IRB) at Manchester
University NHS Trust. In line with the Health Regulatory Authority (HRA) guidelines relating
to data collected as part of routine care, written patient consent was not required as members
of the care team were accessing data collected as part of usual clinical care.
Setting
Manchester Heart Centre (MHC) serves a local population of 213,000 patients, and is a tertiary
referral centre for CIED implantation and extraction for the wider conurbation of Greater
Manchester and Lancashire. In 2016, 120 device extractions were performed at MHC.
Participants
Inclusion and exclusion criteria. Patients aged>18 years who underwent CIED extrac-
tion for infection at MHC between 1st January 2013 and 31st March 2015. Patients who had the
following device types were included: cardiac resynchronization therapy (CRT-D [with defi-
brillator], CRT-P [with pacemaker]), ICDs and permanent pacemakers (PPMs). Patients with
implantable loop recorders and those with infection of temporary pacing systems were
excluded.
Definitions. For the purposes of this analysis, a CIED infection episode was considered to
start on the date of admission to MHC and end on the day of completion of antibiotic therapy
for that episode (or discharge following re-implantation of a new device). CIED infections
were sub-categorized, according to current UK guidelines, into the following groups; CIED-
generator pocket infection (CIED-GPI), CIED-lead infection (CIED-LI), CIED-infective
endocarditis (CIED-IE).[13]
Relapse of infection in the case of CIED-LI/IE was considered to have occurred if blood cul-
tures became positive following initial resolution of clinical signs of infection, with blood cul-
tures/device growing the same microorganism as the previous infective episode (confirmed
with species identification), within 12 months of completing therapy. In the case of CIED-GPI,
relapse was based on clinical evidence of infection occurring within 12 months of the initial
infection episode.
Management strategy. All cases underwent “two-stage” management of their infection.
Patients were classified into two groups: ER cases remained as inpatients for the duration of
their treatment episode; DR cases had the infected device extracted and were discharged prior
to re-implantation of a new device at a later date. In the DR group, the decision to receive out-
patient antimicrobial therapy (OPAT), either parenteral or oral, was on advice of the microbi-
ologists; guided by antimicrobial sensitivities and the trend in blood markers for infection.
Variables and data sources
Baseline demographic data were collected on all patients. The Charlson comorbidity index,
which estimates 10-year mortality according to comorbidity burden, was calculated.[14] The
ongoing need for pacing, and/or defibrillator therapies, was evaluated for all cases. Data con-
cerning type of device extracted, operative duration of extraction, length of inpatient stay
(LOS) and type of device re-implanted were collected from an electronic pacing database.
From these data, the (i) operative procedure cost (ii) device re-implantation cost and (iii) LOS
were calculated and used to determine the total cost of CIED infection per patient (S1 Dataset).
LOS comprised the total number of inpatient days related to the management of the episode of
infection.
Cost of CIED infection
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Cost analysis. The total cost of each CIED infection episode was calculated from the fol-
lowing formula:
Total cost ¼ procedure cost ðextractionþ re   implantationÞ þ cost of inpatient stay
þ cost of life vest ðif applicableÞ þ cost of OPAT ðif applicableÞ:
The procedure cost was calculated by adding the cost of materials used during the case (bar
code analysis of discarded packaging) to the total catheter lab staff cost for the procedure (unit
of laboratory time (ULT)). At MHC, one ULT costs £175, where one ULT equates to 30 min-
utes of staff time (covering the cost of a cardiologist, an anaesthetist, 2 nurses, a cardiac physi-
ologist and a radiographer). Concerning the re-implantation procedure, the cost of the new
device was based on the price paid locally to the manufacturer for that particular model, which
is also recorded in the electronic patient records. The price of the discarded device was not
included in calculations.
The cost of inpatient stay was calculated by multiplying the LOS (days) during the CIED
infection episode by a daily bed cost of £350 per day per bed. Because of the significant addi-
tional cost, use of a Lifevest device was included separately. Cost was calculated from the dura-
tion that the Lifevest was issued to the patient, based on a monthly cost of £4,000 per patient.
Actual cost of inpatient antibiotic therapy was not prospectively recorded in the electronic
database and therefore not available. However, details of OPAT were recorded as a daily tariff
based on the cost of antibiotic therapy.
Bias
We aimed to minimize bias by collecting data on consecutive patients, and to allow assessment
of bias by describing why any eligible patients were excluded.
Study size
The study size was opportunistic and based on the number of consecutive CIED extractions
for infection undertaken at Manchester Heart Centre between 1st January 2013 and 31st March
2015.
Quantitative variables and statistical analysis
Statistical analysis was performed using Prism version 6.0e and R version 3.2.4.[15] Demo-
graphic data are presented as median (IQR) or N (%). Group data were compared using a
Mann-Whitney U-test or Fisher’s exact test, as appropriate. Financial data relating to the cost
of treatment are presented as median (IQR), and compared using Mann Whitney U test. All
tests were two-tailed and P<0.05 was considered statistically significant.
Results
Baseline demographics
Between 1st Jan 2013 and 31st March 2015, 106 patients underwent extraction for CIED-infec-
tion. Complete data relating to the cost of infection was available for 84 patients; 22 patients
were excluded due to incomplete data. Baseline demographic data are presented in Table 1.
Forty-one (48.8%) patients underwent an ER strategy; a DR strategy was used in 43 (51.2%)
patients. At the time of re-implant, 10 (11.9%) patients had an upgrade of their original device
(PPM to CRT, n = 2; ICD to CRT-D, n = 8). Five (27.8%) patients whose original device was a
CRT-D were re-implanted with an ICD only, one patient with a CRT-D was re-implanted
with a CRT-P, and one patient was downgraded from an ICD to PPM at re-implant. A
Cost of CIED infection
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mechanical dilation tool (Evolution controlled rotational dilator system, Cook Medical) was
used in 26 ER and 19 DR cases (p = 0.09).
Four patients had a relapse of CIED-GPI within 12 months of the index infection. A further
two patients died during the index hospitalisation at day 31 and day 9 following PPM extrac-
tion (Case 1, aged 89 year old female with sepsis; Case 2, frail 90 year old male with multiple
co-morbidities).
Table 2 shows the LOS and costs of CIED infection according to re-implantation strategy.
These were analysed according to type of device extracted, as follows:
CRT-D. Of the 18 patients with an infected CRT-D, seven (38.9%) underwent an ER strat-
egy and were re-implanted after a median of 14 days (IQR 8–20); eleven (61.1%) underwent a
DR strategy and were re-implanted a median of 53 days later (IQR 36–91). Of these 11 DR
patients, nine (81.8%) were discharged home with a Lifevest; none of these patients had any
Table 1. Patient demographic data subdivided according to early (ER) or delayed (DR) re-implantation.
Demographics and clinical factors Timing of CIED re-implantation p
Early re-implantation
(n = 41)
Delayed re-implantation
(n = 43)
Median age, years (IQR) 73 (58.0–81.0) 69 (59.0–79.5) 0.594
Median Charlson index (IQR) 2 (0.0–3.0) 2 (1.0–3.5) 0.490
Median age-adjusted Charlson index (IQR) 4 (2.0–6.0) 4 (2.5–6.0) 0.712
Male sex, n (%) 33 (80.5) 36 (83.7) 0.780
Diabetes, n (%) 5 (12.2) 11 (25.6) 0.166
Heart failure (%) 20 (48.8) 25 (58.1) 0.512
CKD�3, n (%) 18 (43.9) 16 (37.2) 0.657
Congenital heart disease, n (%) 2 (4.9) 2 (4.7) 1.000
Prior CIED infection, n (%) 4 (9.8) 5 (11.6) 1.000
Type of CIED infection
CIED-GPI 33 (80.5) 35 (81.4) 1.000
CIED-IE/LI 8 (19.5) 8 (18.6)
Presenting symptoms
Fever 11 (26.8) 10 (23.3) 0.804
Abscess 7 (17.1) 4 (9.3) 0.519
Erosion 12 (29.3) 16 (37.2) 0.488
Purulent discharge 16 (39.0) 17 (39.5) 1.000
Erythema 17 (41.5) 16 (37.2) 1.000
Raised blood markers for infection 17 (41.5) 25 (58.1) 0.190
Positive blood cultures 5 (12.2) 8 (18.6) 0.547
CIED extracted
CRT-D 7 (17.1) 11 (25.6) 0.332
ICD 10 (24.4) 14 (32.6)
PPM 24 (58.5) 18 (41.9)
Lifevest
CRT-D 0 (0.0) 9 (81.8)
ICD 0 (0.0) 9 (64.3)
PPM 0 (0.0) 0 (0.0)
Externalised pacemaker
CRT-D 0 (0.0) 1 (9.1)
ICD 1 (10.0) 4 (28.6)
PPM 5 (20.8) 4 (22.2)
https://doi.org/10.1371/journal.pone.0206611.t001
Cost of CIED infection
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Table 2. LOS and cost of CIED infection according to re-implantation strategy.
ER
(n = 41)
DR
(n = 43)
p
Median cost of index device extraction (cost of extracted device not included), £ (IQR)
All 2,487.59
(1,184.10–3,633.49)
1,339.85
(900.54–3,229.94)
0.250
CRT-D 1,483.24
(1,094.43–3,447.86)
1,046.99
(916.70–4,200.12)
1.000
ICD 3,229.07
(1,880.18–5,161.52)
1,041.42
(922.79–2,113.38)
0.022
PPM 2,290.67
(1,000.74–3,549.99)
1,594.73
(882.36–3,706.37)
0.980
Median length of stay, days (IQR)
All 18 (12–29) 5 (2–9) <0.001
CRT-D 22 (1–27) 6 (5–13) 0.964
ICD 17 (12–23) 3 (2–5) 0.006
PPM 21 (15–30) 5 (1–8) <0.001
Median cost of length of stay, £ (IQR)
All 6,300.00
(4,200.00–10,150.00)
1,750.00
(525.00–2,975.00)
<0.001
CRT-D 7,700.00
(350.00–9,450.00)
2,100.00
(1,750.00–4,375.00)
0.964
ICD 5,775.00
(4,112.50–8,137.50)
875.00
(700.00–1,750.00)
0.006
PPM 7,350.00
(5,162.50–10,500.00)
1,750.00
(350.00–2,800.00)
<0.001
Median time from extraction to re-implant, days (IQR)
All 14 (9–17) 33 (19–72) <0.001
CRT-D 14 (8–20) 53 (36–91) 0.007
ICD 14 (8–16) 56 (20–72) 0.003
PPM 15 (12–16) 25 (15–33) 0.035
Re-implant device cost, £ (IQR)
All 2,356.93
(1,412.69–12,150.00)
1,913.00
(1,181.85–9,374.74)
0.175
CRT-D 12,408.24
(10,941.00–12,996.97)
9,567.67 and 12,531.02� 0.659
ICD 12,996.88
(10,941.00–13,310.88)
9,374.74
(8,473.99–12,203.90)
0.015
PPM 1,914.61
(1,100.00–2,064.15)
1,181.85
(1,100.00–1,477.67)
0.173
Grand total cost of CIED infection (without Lifevest included), £ (IQR)
All 14,241.48
(10,750.67–21,518.75)
12,252.68
(5,351.00–14,718.75)
0.003
CRT-D 20,049.00
(13,032.54–25,108.57)
16,026.74
(14,038.21–18,537.46)
0.659
ICD 22,077.18
(18,767.52–26,553.92)
12,472.91
(8,883.56–13,946.49)
<0.001
PPM 11,213.20
(8,634.09–15,881.56)
5,351.00
(3,155.02–10,873.82)
0.002
Lifevest cost, £ (IQR)
All N/A 10,000
(8,000–15,000)
CRT-D N/A 8,000
(8,000–24,000)
(Continued)
Cost of CIED infection
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arrhythmia detected or received therapy. One patient who had an externalized pacemaker
(and was thus not suitable for a Lifevest) requested to be managed as an outpatient pending
device re-implant. Another, who had had an ICD for 13 years with no therapy, requested a
downgrade to a CRT-P, and therefore did not receive a Lifevest.
ICD. Twenty-four patients had an infected ICD. Ten (41.7%) underwent an ER strategy a
median of 14 days following extraction (IQR 8–16). Fourteen (58.3%) patients underwent a
DR strategy and with re-implantation a median of 56 days later (IQR 20–72) (Table 2). Of
these, nine (81.8%) patients received a Lifevest. Four patients who required an externalised
pacemaker requested outpatient management so were unsuitable for a Lifevest, while one
patient was downgraded to a pacemaker at re-implant.
Pacemakers. Twenty-four of 42 (57.1%) PPM patients underwent an ER strategy a
median of 15 days later (IQR 12–16). An externalized temporary pacemaker was required in
five (20.8%) of these cases following extraction. Eighteen (42.9%) PPM patients underwent a
DRstrategy and were discharged with re-implantation a median 25 days later (IQR 15–33). An
externalized temporary pacemaker was used in four (22.2%) cases.
Length of hospitalisation. When all device types were considered, total LOS was signifi-
cantly shorter in patients managed via a DR strategy compared to an ER strategy (median 5 vs.
18 days, p<0.001). Those with either ICD or PPM in the DR group had significantly shorter
LOS compared to similar patients in the ER group, [(ICD 3 vs. 17 days, p = 0.006) (PPM 5 vs.
21 days, p<0.001)]. Median LOS for patients with CRT-D was not significantly different (6 vs.
22 days, p = 0.964), however ER CRT-D comprised only seven patients with LOS located at
both extremes of the range. Cost of hospitalization, attributable to bed costs, was significantly
higher in ER patients (£6,300.00 vs £1,750.00; p<0.001) (Table 2). No patients required an
intensive care unit (ICU) admission in either group.
Table 2. (Continued)
ER
(n = 41)
DR
(n = 43)
p
ICD N/A 12,000
(4,000–12,000)
Grand total (including Lifevest cost), £ (IQR)
All 14,241.48
(10,750.67–21,518.75)
14,739.74
(5,136.20–24,238.74)
0.491
CRT-D 20,049.00
(13,032.54–25,108.57)
24,315.80
(22,645.38–37,179.48)
0.056
ICD 22,077.18
(18,767.52–26,553.92)
18,174.94
(9,481.27–25,938.74)
0.192
PPM 11,213.20
(8,634.09–15,881.56)
5,136.20
(3,155.02–10,873.82)
0.001
Grand total (including Lifevest cost and outpatient antibiotics), £ (IQR)
All 14,241.48
(10,750.67–21,518.75)
14,741.70
(5,139.14–24,253.93)
0.491
CRT-D 20,049.00
(13,032.54–25,108.57)
24,318.17
(22,727.97–37,193.48)
0.056
ICD 22,077.18
(18,767.52–26,553.92)
18,178.37
(9,481.27–25,938.74)
0.192
PPM 11,213.20
(8,634.09–15,881.56)
5,139.14
(3,158.26–10,891.56)
0.001
�Individual values due to small numbers
https://doi.org/10.1371/journal.pone.0206611.t002
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Cost analysis
For the total cohort of 84 cases, the median cost of a CIED extraction procedure was £1,729.95
(£942.41 – £3,588.90), and the cost of inpatient stay was £3,150 (£700.00 – £7,700.00).
Extraction procedure-related costs. Although the median cost of the CIED extraction
procedure was higher for ER compared to DR, the difference was not statistically significant
(£2,487.59 vs £1,339.85 respectively; p = 0.250) (Table 2). This cost takes into consideration the
staff, equipment and facility-related costs for operative interventions.
Outpatient antibiotic therapy. Twenty-two (51.2%) of DR cases received OPAT prior to
CIED re-implantation. Of these, one patient received intravenous OPAT; the remainder
received oral treatment (flucloxacillin, n = 12; linezolid n = 5; other antibiotic n = 4). Median
duration of outpatient treatment was 14 (12.5–14.0) days. Median cost was £3.47 (1.96–20.66).
The staffing costs associated with administering IV antibiotics in the community were not
calculated.
Cost of CIED infection episode according to device type. When all cases were consid-
ered, the cost of infection ranged £5,139 (PPM) to £24,318 (CRT-D).
The cost of the Lifevest increased the overall costs in the DR group by a median of
£10,000.00; prior to the addition of Lifevest and OPAT costs, the cost of CIED infection epi-
sodes was significantly less in the ER group (£14,241.48 vs £12,252.68, p = 0.003). However,
when the cost of the Lifevest and OPAT were taken into account, the total cost of CIED infec-
tion was similar in the ER and DR groups (£14,241.48 vs £14,741.70, respectively; p = 0.491). It
should be noted that not all patients in whom a defibrillator was extracted (ICD or CRT-D) in
the DR group received a Lifevest whilst awaiting re-implantation. Reasons for this included
incompatibility with externalised pacemakers (1 CRT-D patient, 4 ICD patients), planned
downgrade at re-implant (1 CRT-D patient, 1 ICD patient) and patient choice, i.e. patients
unwilling to wear the Lifevest who accepted the short-term risk of untreated ventricular
arrhythmias. When the groups were split according to type of CIED extracted (CRT-D, ICD
or PPM), the total cost of CIED infection episode was significantly higher in ER cases com-
pared to DR cases for PPM devices only (£11,213.20 vs £5,139.14; p = 0.001) (Table 2).
Cost of episode according to type of CIED infection
Types of CIED infection are shown in Table 1. Because the number of cases of CIED-LI was
relatively small (n = 3), the cases of CIED-IE and CIED-LI were combined for analysis. We
examined cases according to the type of infection diagnosed; CIED-GPI (n = 68) and CIE-
D-IE/LI (n = 16) (Table 3). The median total cost of CIED-GPI was £12,741.93, compared to
£18,200.26 for cases of CIED-LI/IE (p = 0.105). The cost of operative intervention, relating to
extraction of the infected device, was not significantly different between the two types of infec-
tion (CIED-GPI £2,121.49 vs £1,329.12; p = 0.214). LOS was significantly longer for cases of
CIED-LI/IE compared to CIED-GPI (15 vs. 8 days; p = 0.029). Although the time from CIED
extraction to re-implant was longer for cases of CIED-LI/IE compared to CIED-GPI, this was
not statistically significant (30.0 vs. 16.0 days; p = 0.106).
Discussion
This is the largest study to evaluate the cost of CIED infection in the UK. We found that a DR
strategy, whereby the patient is discharged after CIED extraction with re-implantation at a
later date (on a daycase basis), is feasible and associated with no overall cost penalty, taking
into account all device types. Lower costs for DR were seen for PPM infections, due to reduced
LOS. There was a trend towards higher overall cost in the CRT-D group managed using a DR
Cost of CIED infection
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Table 3. LOS and cost of CIED infection according to type of infection (CIED GPI vs. CIED LI/IE).
CIED-GPI
(N = 68)
CIED-LI/IE
(N = 16)
p
Median cost of index device extraction (cost of extracted device is not included), £ (IQR)
All cases 2,121.49
955.54–3,695.64
1,329.12
887.97–2,126.28
0.214
CRT-D 2,908.09
770.16–4,741.06
1,042.87
998.25–1,156.05
0.442
ICD 2,149.23
1,040.06–4,203.67
1,482.75
1,103.71–1,844.33
0.296
PPM 1,848.27
921.30–3,554.42
2,078.50
882.15–3,549.99
1.000
Median length of stay, days (IQR)
All cases 8 (2–19) 15 (7–44) 0.029
CRT-D 9 (5–24) 5 (1–19) 0.631
ICD 4 (2–15) 8 (5–20) 0.293
PPM 10 (2–21) 41 (16–47) 0.005
Median cost of length of stay, £ (IQR)
All cases 2,625.00
(700.00–6,562.50)
5,075.00
(2,537.50–15,400.00)
0.029
CRT-D 2,975.00
(1,750.00–8,225.00)
1,750.00
(350.00–6,475.00)
0.631
ICD 1,225.00
(700.00–5,075.00)
2,800.00
(1,750.00–7,000.00)
0.293
PPM 3,500.00
(700.00–7,350.00)
14,350.00
(5,512.50–16,275.00)
0.005
Median time from extraction to re-implant, days (IQR)
All cases 16
(14–33)
30
(20–69)
0.106
CRT-D 33
(19–54)
100
(51–206)
0.449
ICD 17
(14–60)
20
(15–33)
0.867
PPM 15
(13–18)
30
(28–53)
0.019
Re-implant device cost, £ (IQR)
All 2,356.93
(1,181.85–10,941.00)
2,553.76
(1,412.69–10,941.00)
0.628
CRT-D 10,941.00
(10,254.33–12,996.97)
12,408.24 and 12,531.02 0.883
ICD 12,150.00
(9,374.74–13,263.00)
10,941.00
(10,549.43–11,270.20)
0.559
PPM 1,181.85
(1,100.00–1,996.20)
1,412.69
(1,288.15–1,996.20)
0.462
Grand total cost of CIED infection before life vest, £ (IQR)
All 11,819.42
(7,878.16–15,585.93)
15,996.37
(13,722.47–19,505.43)
0.028
CRT-D 17,869.81
(13,844.91–21,911.97)
15,134.11
(14,161.05–16394.30)
0.574
ICD 13,781.73
(11,262.33–21,200.92)
15,431.83
(14,455.88–19,269.87)
0.388
PPM 9,324.07
(5,151.98–11,686.68)
18,270.59
(8,860.31–20,529.31)
0.022
Lifevest cost
(Continued)
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strategy and also higher overall cost for CIED-LI/IE compared to CIED-GPI cases, though
these were not statistically significant.
US data indicates that the combined medical and surgical cost for treatment of CIED infec-
tion has increased by 47% over the last 20 years.[1] While the bulk of expense may be attrib-
uted to the cost of the re-implanted device and procedure, there are other significant expenses
that contribute, including diagnostic investigations, medical (e.g. intravenous antibiotics) and
surgical intervention, and prolonged hospital stay. Sohail et al. reported the mean adjusted
cost of admissions related to CIED infection to range from $28,676 to $53,349 depending on
the type of device infected (PPM- $28,676, CRT-P- $39,410, ICD- $47,543, CRT-D- $53,349),
where almost half of the incremental cost was attributable to stay on an intensive care unit.(8)
In another study, compared to CIED patients without infection, the incremental healthcare
expenditure for patients with CIED infection occurring within 12 months of index implanta-
tion requiring in- or out-patient extraction for infection was $45,291, and $279,744 for those
with severe sepsis requiring in-patient extraction.[16]
Thus far, there have been only limited UK data.[17] One prior study of 30 cases in 2014
reported the UK cost of CIED infection to be approximately £30,958.40, similar to US studies,
[8, 11, 12] but higher than we report in the current study (median £14,491.59). This may be
partly explained by the fact that, our population contained a larger number of lower power
devices (PPM; n = 42) compared to the previous analysis (PPM; n = 8). Moreover, in the study
by Ahsan et al, calculation of post-extraction care included critical care (level 3) stay, compared
Table 3. (Continued)
CIED-GPI
(N = 68)
CIED-LI/IE
(N = 16)
p
All cases 8,000
8,000–12,000
4,000 16,000 40,000�
CRT-D 8,000
8,000–16,000
16,000 & 40,000
ICD 12,000
7,000–12,000
4,000
Received externalized pacemaker 13 2
Grand total cost of CIED infection, £ (IQR)
All 12,741.93
(7,196.04–22,707.29)
18,197.32
(13,963.76–22,914.12)
0.105
CRT-D 23,647.89
(20,575.91–28,824.90)
24,761.87
(16,683.11–37,500.00)
0.959
ICD 21,306.86
(14,414.86–26,218.39)
17,431.83
(15,257.15–21,468.61)
0.852
PPM 9,324.07
(5,088.22–11,687.68)
18,270.59
(8,860.31–20,529.31)
0.018
Grand total cost of CIED infection with antibiotics, £ (IQR)
All 12,741.93
(7,196.04–22,707.29)
18,200.26
(13,963.76–22,914.12)
0.105
CRT-D 23,675.89
(20,610.21–28,824.90)
24,767.19
(16,683.11–37,507.98)
<0.001
ICD 21,306.86
(14,416.33–26,218.58)
17,434.76
(15,257.15–21,473.02)
<0.001
PPM 9,324.07
(5,089.69–11,686.68)
18,270.59
(8,908.31–20,529.31)
<0.001
�Only three patients in this group receive a Lifevest, therefore statistical test not appropriate due to low number of cases.
https://doi.org/10.1371/journal.pone.0206611.t003
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to coronary care unit (level 2) in the current study.Finally, Ahsan et al. included the cost of inpa-
tient antimicrobial treatment, which although this does not constitute the bulk of additional
cost, is a limitation of our study.[12] European data is also sparse. In a single centre study,
which included 7 pacemaker infections, Kuehn et al. reported that the mean additional hospital
costs for infected cases was €7091.[17] More recently, a retrospective analysis of German health
claims data has indicated that the incremental healthcare expenditure for patients with CIED
infection ranged from €31,493 for denovo infections to €59,419 for major infections.[18]
When all cases were considered, median (IQR) LOS was 9 (2–22) days for all CIED infec-
tions. The PPM group had the highest median LOS at 15 (5–24) days. Interestingly, we report
longer LOS with low energy devices (PPM) compared to ICD/CRT-D, although this was not
statistically significant (15 days vs. 8 days; p = 0.571). US data indicates that the mean adjusted
LOS for CIED infection ranged from 15.5 to 24.3 days depending on the type of device (PPM
15.5, CRT-P 24.3, ICD 18.8, CRT-D 17.1 days). The incremental LOS with infection ranged
from 9.4 to 18.2 days.[8]
Very early re-implant strategies, with CIED re-insertion 72 hours post-extraction, have also
been described,[19] although this is not currently practiced at our institution. In the current
study, median time from extraction to re-implant for ER cases was 14 days, compared to 33
days in the DR group (p<0.001).
We have demonstrated that a DR strategy is feasible, and that whilst the costs per individual
range considerably, the overall cost for adoption of such a strategy is cost neutral, even taking
into account the cost of a Lifevest for ICD patients. The authors believe that the additional ben-
efit of LOS reduction (e.g. the ability to use hospital beds to treat other patients) makes a strong
case for using the DR strategy in the UK.
Limitations
Although the principle indication for being stratified to a DR treatment strategy is usually per-
sistent or slow healing infection, there is the possibility of some such patients being in the ER
group due to other circumstances. We acknowledge this as a limitation of a retrospective
observational study but, as this was a single-centre study with fairly homogenous clinical prac-
tice amongst our specialists, we expect the impact of this limitation to minimal. Furthermore,
as cases of device infection are discussed in a dedicated MDT meeting, significant variation in
usual care is limited.
Our study has several limitations that may underestimate the cost of infection. As some
patients had re-implantation performed at their local hospitals, the number of cases included was
reduced from 106 to 84 and thus some of the subgroups contained small numbers. Costs incurred
via diagnostic procedures and some costs relating to treatment of infection (e.g. delivering intrave-
nous antibiotics) were not included, although we do not feel that these represented a major con-
founding factor. Regarding LOS, we report the longest LOS in the PPM cohort, however this is
likely to be underestimated as 20 PPM patients were transferred as inpatients from their local hos-
pitals for extraction, and we do not include the additional LOS incurred at those hospitals.
The costs quoted are based on prices paid by our centre, however these may vary across the
UK. The ULT used to calculate staff and logistical costs for each procedure was derived from a
local model, and we recognise that this cost may not be generalizable as the make-up of the
catheter lab team may vary between centres; indeed, in some hospitals CIED extraction is per-
formed by cardiac surgeons in an operating theatre. Finally, the cost analysis in this study only
examines the cost of inpatient treatment and does not take into consideration any outpatient
appointments, investigations or previous hospitalisations relating to a particular episode of
infection.
Cost of CIED infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0206611 January 2, 2019 11 / 13
Conclusion
CIED infections are expensive and associated with significant health economic burden due to
prolonged hospitalization, procedural and device costs. Consideration of different approaches
to management of CIED infection, such as a DR strategy for those patients with delayed heal-
ing or infection that is slow to fully resolve, may help to mitigate the cost of CIED infection
and warrants further prospective evaluation provided the approaches are as efficacious and
not associated with a higher rate of adverse events.
Supporting information
S1 Dataset. PLOS_minimal dataset_Aug_2018.
(XLSX)
Author Contributions
Conceptualization: Fozia Zahir Ahmed, Jonathan Sandoe.
Data curation: Fozia Zahir Ahmed, Mahvash Zaman.
Formal analysis: Fozia Zahir Ahmed, Catherine Fullwood.
Investigation: Catherine Fullwood, Mahvash Zaman, Ahmed Qamruddin.
Methodology: Fozia Zahir Ahmed, Catherine Fullwood.
Software: Catherine Fullwood.
Validation: Catherine Fullwood.
Writing – original draft: Fozia Zahir Ahmed, Catherine Fullwood, Colin Cunnington, Jona-
than Sandoe, Manish Motwani, Amir Zaidi.
Writing – review & editing: Fozia Zahir Ahmed, Catherine Fullwood, Colin Cunnington,
Mamas A. Mamas, Jonathan Sandoe, Manish Motwani, Amir Zaidi.
References
1. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. 16-year trends in the infection bur-
den for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am
Coll Cardiol. 2011; 58(10):1001–6. https://doi.org/10.1016/j.jacc.2011.04.033 PMID: 21867833
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of car-
diac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352(15):1539–
49. https://doi.org/10.1056/NEJMoa050496 PMID: 15753115
3. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicen-
ter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335(26):1933–40.
https://doi.org/10.1056/NEJM199612263352601 PMID: 8960472
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defi-
brillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346
(12):877–83. https://doi.org/10.1056/NEJMoa013474 PMID: 11907286
5. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United
States: 1996 through 2003. J Am Coll Cardiol. 48. United States2006. p. 590–1. https://doi.org/10.
1016/j.jacc.2006.05.016 PMID: 16875991
6. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. Trends in permanent pacemaker
implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures.
J Am Coll Cardiol. 2012; 60(16):1540–5. https://doi.org/10.1016/j.jacc.2012.07.017 PMID: 22999727
7. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device
infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol.
2010; 33(4):414–9. https://doi.org/10.1111/j.1540-8159.2009.02569.x PMID: 19793359
Cost of CIED infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0206611 January 2, 2019 12 / 13
8. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with
cardiovascular implantable electronic device infections. Arch Intern Med. 2011; 171(20):1821–8.
https://doi.org/10.1001/archinternmed.2011.441 PMID: 21911623
9. Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pace-
maker implantation: Infection rates and risk factors associated with infection in a population-based
cohort study of 46299 consecutive patients. European Heart Journal. 2011; 32(8):991–8. https://doi.
org/10.1093/eurheartj/ehq497 PMID: 21252172
10. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004; 350
(14):1422–9. https://doi.org/10.1056/NEJMra035415 PMID: 15070792
11. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D, et al. Cardiac implantable electronic device
infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm.
2014; 11(4):595–601. https://doi.org/10.1016/j.hrthm.2013.12.013 PMID: 24333543
12. Ahsan SY, Saberwal B, Lambiase PD, Koo CY, Lee S, Gopalamurugan AB, et al. A simple infection-
control protocol to reduce serious cardiac device infections. Europace. 2014; 16(10):1482–9. https://
doi.org/10.1093/europace/euu126 PMID: 24919539
13. Harrison JL, Prendergast BD, Sandoe JA. Guidelines for the diagnosis, management and prevention of
implantable cardiac electronic device infection. Heart. 2015; 101(4):250–2. https://doi.org/10.1136/
heartjnl-2014-306873 PMID: 25550318
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity
in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383. PMID: 3558716
15. R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria. URL http://www.R-project.org/.
16. Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ. Incidence, Treatment Inten-
sity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic
Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation. Circ Arrhythm
Electrophysiol. 2016; 9(8).
17. Kuehn C, Graf K, Heuer W, Hilfiker A, Chaberny IF, Stiesch M, et al. Economic implications of infections
of implantable cardiac devices in a single institution. Eur J Cardiothorac Surg. 2010; 37(4):875–9.
https://doi.org/10.1016/j.ejcts.2009.10.018 PMID: 19939696
18. Ludwig S, Theis C, Brown B, Witthohn A, Lux W, Goette A. Incidence and costs of cardiac device infec-
tions: retrospective analysis using German health claims data. J Comp Eff Res. 2018; 7(5):483–92.
https://doi.org/10.2217/cer-2017-0080 PMID: 29132224
19. Podoleanu C, Deharo JC. Management of Cardiac Implantable Electronic Device Infection. Arrhythm
Electrophysiol Rev. 2014; 3(3):184–9. https://doi.org/10.15420/aer.2014.3.3.184 PMID: 26835089
Cost of CIED infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0206611 January 2, 2019 13 / 13
